Post-COVID-19 syndrome in outpatients: a cohort study

Florian Desgranges[1], Eliana Tadini[1], Aline Munting[1], Jean Regina[1], Paraskevas Filippidis[1], Benjamin Viala[1], Eleftherios Karachalias[2], Véronique Suttels[1], David Haefliger[1], Eleftheria Kampouri[1,3], Mathias Van Singer[1], Jonathan Tschopp[1], Laurence Rochat Stettler[1], Siméon Schaad[1], Thomas Brahier[1], Olivier Hugli[4], Yolanda Mueller Chabloz[5], Alexandre Gouveia[5], Onya Opota[6], Pierre-Nicolas Carron[4], Benoît Guery[1], Matthaios Papadimitriou-Olivgeris[1]*, Noémie Boillat-Blanco[1]*, the RegCOVID research group.

* Equal contribution to this work

Members of the RegCOVID group are listed in the acknowledgement section

[1]Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Switzerland; [2]Data Scientist, Cardiff, England; [3]Service of Hospital Preventive Medicine, Lausanne University Hospital and University of Lausanne, Switzerland; [4]Emergency Department, University Hospital of Lausanne and Lausanne University, Switzerland; [5]Department of Family Medicine, Center for Primary Care and Public Health (Unisanté), University of Lausanne, Switzerland; [6]Institute of Microbiology, Lausanne University and University Hospital of Lausanne, Switzerland

Word count:

- Abstract: 263
- Manuscript: 2986

ABSTRACT

Background

Some patients experience long-term symptoms after COVID-19, but data on outpatients with mild-to-moderate COVID-19 are scarce.

Objective

To describe persisting symptoms more than 3 months after infection in PCR-confirmed COVID-19 in comparison to negative SARS-CoV-2 PCR outpatients and to identify predictors of long-term symptoms in COVID-19.

Setting

Outpatient clinics of a Swiss university center.

Patients

418 symptomatic outpatients with PCR-confirmed COVID-19 (COVID-positive) and 89 negative SARS-CoV-2 PCR (COVID-negative).

Design

Prospective cohort study.

Measurements

Predefined long-term symptoms were evaluated though a phone interview >3 to 10 months after diagnosis.

Associations between long-term symptoms and PCR test result, as well predictors of persisting symptoms in COVID-positive were evaluated by multivariate logistic regression including potential confounders (age, sex, smoking, comorbidities, time of the phone survey).

Results

The study population consisted mostly of young (median of 41 versus 36 years in COVID-positive and COVID-negative, respectively; p=0.020) health care workers (67% versus 82%;

p=0.006).. Persisting symptoms were reported by 223 (53%) COVID-positive and 33 (37%) COVID-negative (*p*=0.006). Overall, 21% COVID-positive and 15% COVID-negative (p=0.182) consulted a doctor for these symptoms. Four surveyed symptoms were independently associated with COVID-19: fatigue (adjusted odds ratio [aOR] 2.14, 95%CI 1.04-4.41), smell/taste disorder (26.5, 3.46-202), dyspnea (2.81, 1.10-7.16) and memory impairment (5.71, 1.53-21.3). Among COVID-positive, female gender (aOR 1.67, 95% CI 1.09-2.56) and overweight/obesity (1.67, 1.10-2.56) were predictors of persisting symptoms.

Limitations

Undiagnosed SARS-CoV-2 infection in COVID-negative cannot be completely excluded.

Conclusion

More than half of COVID-positive outpatients report persisting symptoms up to 10 months after infection and 21% seek medical care for this reason. These data suggest that post-COVID syndrome places a significant burden on society and especially healthcare systems.

INTRODUCTION

More than one year after the first cases of Coronavirus disease 2019 (COVID-19) (1), the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic remains a constant threat challenging the capacity of healthcare systems and affecting well-being of many individuals. The clinical presentation and outcome of acute COVID-19 is well described, most patients presenting with mild disease and only a minority needing hospital admission (2). While most affected people experience complete resolution of their symptoms after two to six weeks (3,4), symptoms lasting more than 3 months have been reported in social media (5–7) and in observational studies (8–13). Three studies reported that a large number of patients have persisting symptoms for more than 6 months after COVID-19: one study including adults discharged from hospital (14) and two studies including outpatients with mild-to-moderate disease (15,16). Recent guidelines defined post-COVID-19 syndrome as the persistence of signs and symptoms for more than 3 months after infection in the absence of an alternative diagnosis (17).

Although they represent the vast majority of cases, data on long-term consequences in outpatients with mild-to-moderate COVID-19 are still scarce. To the best of our knowledge, no study compared the prevalence of persisting symptoms among patients screened for similar symptoms, between those tested positive for SARS-CoV-2 and those tested negative. Therefore, the association between PCR-confirmed COVID-19 and long-term symptoms is not well established. Furthermore, no study explored the factors associated with persisting symptoms in outpatients. These data are crucial as they may modify patients' follow-up after their infection and influence public health vaccination strategies by identifying additional population groups that should be prioritized.

We aimed to compare the prevalence of symptoms persisting for more than 3 months

between SARS-CoV-2 PCR-confirmed (COVID-positive) and PCR-negative (COVID-negative)

patients in outpatient clinics, and to identify predictors of persisting symptoms in COVID-

positive.

METHODS

Study design, setting and participants

This cohort study recruited consecutive PCR-confirmed COVID-19 patients (COVID-positive

group) during their initial visit in the emergency department (ED) or in the SARS-CoV-2

screening center of the University hospital of Lausanne, as well as in the two outpatient clinics

of the University of Lausanne, Switzerland, between February 26th and April 27th 2020. During

the study period, SARS-CoV-2 screening was restricted to symptomatic patients (i.e.

symptoms of acute respiratory tract infection, anamnestic fever or sudden loss of smell or

taste) with at least one risk factor for severe COVID-19 (i.e. ≥ 65 years old or presence of a

comorbidity such as hypertension, diabetes, cancer, chronic cardiac or respiratory disease,

immunosuppression) and to symptomatic health workers (18). Validated nucleic acid

amplification tests were used and a dedicated trained medical team performed the

nasopharyngeal swabs (19).

We included a control group of outpatients attending the same health facilities during the

same period with symptoms suggestive of COVID-19 (cough and/or dyspnea) at presentation,

but a negative PCR SARS-CoV-2 result in nasopharyngeal swab (COVID-negative group). This

group was part of a prospective cohort of patients with acute respiratory infections previously

described (20,21).

We excluded patients who 1) did not have a documented health assessment at the time of

the test, 2) were hospitalized (for more than 24 hours) on the day of initial visit or within the

following 30 days, 3) were unable to understand the phone survey due to a language barrier

or a cognitive impairment, 4) declined to participate, 5) were not reachable for the phone

interview after at least two attempts or 6) had the phone survey less than 3 months after the

initial visit. Patients who had a positive SARS-CoV-2 test performed in another location before

the initial visit in the study centers were excluded, as we also planned to evaluate the impact

of the infection on healthcare system (i.e. medical consultations for persisting symptoms).

Moreover, we excluded COVID-negative patients who declared having a documented (PCR or

serology) SARS-CoV-2 infection after the initial consultation up to the phone follow-up.

Procedures

We retrospectively extracted data from the patients' electronic medical records:

demographics, medical history, initial clinical presentation, and SARS-CoV-2 real-time reverse

transcriptase PCR (RT-PCR) cycle thresholds. We prospectively conducted a structured and

standardized phone survey more than 3 three months after SARS-CoV-2 diagnosis to collect

information on (1) persisting symptoms at the time of the call, (2) secondary hospital

admission within 30 days of the initial consultation, (3) medical consultation for persisting

symptoms until the call, and (4) anthropometric data. The survey included 14 pre-defined

symptoms: fatigue, muscle weakness, dyspnea, cough, thoracic pain, smell or taste disorder,

blurred vision, headache, memory impairment, loss of balance, numbness, nausea, sleep

disorder, and hair loss. Dyspnea was further categorized according to New York Heart

Association (NYHA) grades (22). The calls were performed by physicians of the infectious

diseases service of the University Hospital of Lausanne.

All data were entered in the Lausanne University Hospital's electronic database "regCOVID"

using the REDCap® platform (Research Electronic Data Capture v8.5.24, Vanderbilt University,

Tennessee, USA) (20,23).

Definitions

Long-term symptoms were defined as symptoms that appeared during the acute infection

phase, were still present at time of the phone call (i.e. >3 months after the initial consultation)

and were not explained by an alternative diagnosis. Smell or taste disorder included partial or

complete loss of that sense. Numbness included hypoesthesia and paresthesia.

To account for the timing of symptoms assessment, we classified COVID-positive patients in

three equivalent periods according to the time between SARS-CoV-2 diagnosis (initial

consultation) and the phone interview: first period: >3 months to 5 months after diagnosis,

second period: >5 months to 7 months after diagnosis, and third period: >7 months to 10

months after diagnosis.

Statistical analyses

Demographics, clinical features at the time of initial consultation, consultation for persisting

symptoms and prevalence of long-term symptoms (any symptom or individualized symptoms)

were compared between COVID-positive and COVID-negative by Mann Whitney-U, *chi-*

squared, or Fisher tests as appropriate, as well as between COVID-positive patients surveyed

during the three different periods after SARS-CoV-2 diagnosis by 1-way ANOVA, Kruskal-Wallis

or chi-squared as appropriate. A *p* value <0.05 was considered statistically significant. The

association between COVID-19 and long-term symptoms was evaluated by multivariate

logistic regression including potential confounders (age, sex, smoking, comorbidities, period

of the phone survey). The independent association between the previously mentioned factors

and long-term symptoms in COVID-positive was evaluated by multivariate logistic regression

including the same potential confounders.

STATA (version 15.1, Stata Corp, College Station, TX, USA) statistical software and GraphPad

Prism 8.3 (GraphPad, San Diego, CA, USA) were used for analyses.

Ethics

The project was approved by the Ethics Committee of the Canton of Vaud, Switzerland. All

participants gave their verbal consent to participate in this study during the phone interview

(project-ID CER-VD 2020-01107 and 2019-02283).

RESULTS

A total of 956 symptomatic patients had a RT-PCR-confirmed COVID-19 between February 26th

and April 27th, 2020. We excluded 198 patients who were admitted within 30 days of the initial

visit (151 on the day of the first visit and 47 in the following 30 days) and 340 with other

exclusion criteria described in Figure 1. The remaining 418 (44%) COVID-positive patients were

included in the analysis. We contacted 131 COVID-negative patients who consulted with

symptoms suggestive of COVID-19 and had a negative SARS-CoV-2 RT-PCR between March

31st and April 26th, 2020. We excluded 19 patients who had a positive SARS-CoV-2 test (RT-

PCR or serology) between the time of the initial visit and the time of the phone survey, 17 who

could not be reached, 3 who refused to participate, 2 who did not speak one of the

investigators' languages and one who died. The remaining 89 (68%) COVID-negative patients

were included in the analysis.

Demographics and clinical presentation

In both groups, there was a majority of women and health care workers. Approximately a third

of patients suffered from a comorbidity, mainly obesity, arterial hypertension, and asthma

(Table 1). Most patients were tested within the first week of symptom onset and had normal

vital signs at initial consultation. Compared to COVID-negative, COVID-positive were slightly

older and less often health care workers, active smokers, and asthmatic. COVID-positive

reported less often a history of fever, dyspnea, or sore throat at the time of evaluation.

The study team assessed long-term symptoms via the phone survey at a median of 105 days

(interquartile range [IQR], 121-204 days) and 242 days (IQR 236-248 days) after the initial

consultation in the COVID-positive and COVID-negative groups, respectively ($p<0.001$). The

study team called 190 (45%) COVID-positive during the first period (>3 to 5 months after the

initial visit), 102 (24%) during the second period (>5 to 7 months) and 126 (30%) during the

third period (>7 to 10 months). Patients surveyed in the first period were significantly older,

less often health-care workers and had more comorbidities than those in the two other

periods (Appendix Table 1). The study team called all COVID-negative during the third period.

Long-term symptoms

At the time of the phone survey, 223/418 (53%) COVID-positive and 33/89 (37%) COVID-

negative patients ($p=0.006$) reported the presence of any long-term symptom (Figure 1A,

Table 2).

In COVID-positive, the main reported symptoms were fatigue (n=132, 32%), smell or taste

disorder (n=93, 22%), dyspnea (n=66, 16%), headache (n=50, 12%), memory impairment

(n=48, 11%), hair loss (n=43, 10%), and sleep disorder (n=41, 10%). The prevalence of long-

term symptoms was similar during the 3 periods surveyed (Figure 2B). In COVID-negative, the

main reported symptoms were fatigue (n=15, 17%), headache (n=10, 11%), sleep disorder

(n=10, 11%), and dyspnea (n=7, 8%).

COVID-positive reported more often smell or taste disorder (p=0.001), fatigue (p=0.006) and

memory impairment (p=0.003) than COVID-negative. The prevalence of other symptoms was

similar between COVID-positive and COVID-negative. The proportions of patients with ≥ 2 and

≥ 3 symptoms were greater in COVID-positive than COVID-negative (38% *vs* 19%; *p*=0.001 and

23% *vs* 9.0 %; *p*=0.002, respectively). The proportion of patients requiring a medical

consultation for persisting symptoms was similar between COVID-positive and COVID-

negative (21% versus 15%, p=0.182).

Independent association between COVID-positive status and long-term symptoms

After adjusting for potential confounders, COVID-positive status was a predictor for reporting

any symptom (adjusted odds ratio [aOR] 2.04, 95% CI 1.14-3.67; *p*=0.02), fatigue (aOR 2.14,

95% CI 1.04-4.41; *p*=0.04), dyspnea (aOR 2.81, 95% CI 1.10-7.16; *p*=0.03), smell or taste

disorder (aOR 26.5, 95% CI 3.46-202; p<0.01) and memory impairment (aOR 5.71, 95% CI 1.53-

21.3; p=0.01) at the time of the phone survey (Table 2). Of note, dyspnea associated with

limited physical activity (NYHA ≥2), as well as other long-term symptoms were not associated

with COVID status.

Predictors of long-term symptoms in COVID-positive

While 57% of women presented long-term symptoms, only 47% of men did (p=0.049). While

59% of overweight/obese patients presented long-term symptoms, only 49% of patients with

healthy weight did (p=0.041). After adjusting for potential confounders, independent

predictors of reporting any long-term symptoms were still female gender (aOR 1.67, 95% CI

1.09-2.56; p=0.019) and overweight/obesity (aOR 1.67, 95% CI 1.10-2.56; p=0.017; Table 3).

The same predictors were associated with long-term fatigue. Predictor of dyspnea was

overweight/obesity. Predictor of smell or taste disorder was female gender. Predictor of

memory impairment was active smoking (Figure 3). Predictors of other long-term symptoms,

which were not associated with COVID status, are presented in Appendix table 2.

DISCUSSION

In a large cohort of PCR-confirmed COVID-19 outpatients, we evaluated the prevalence of persisting symptoms 3 to 10 months after diagnosis and compared it with a cohort of negative SARS-CoV-2 PCR patients included during the same period with a similar clinical presentation. In these study populations consisting mostly of young and healthy participants, most working as health care workers, we showed that 53% of patients with PCR-confirmed COVID-19 report persisting symptoms, while 37% with negative SARS-CoV-2 PCR do. Interestingly, only 4 out of the 14 surveyed persisting symptoms were independently associated with COVID status, i.e. fatigue, smell or taste disorder, dyspnea and memory impairment.

The type and prevalence of long-lasting symptoms in COVID-positive are consistent with existing literature. In a systematic review and meta-analysis of studies evaluating the prevalence of persisting symptoms up to 110 days after COVID-19 of various severities, the five more common symptoms were fatigue (58%), headache (44%), attention disorder (27%), hair loss (25%) and dyspnea (24%), while ageusia, anosmia and memory loss were reported by 23%, 21% and 16% of the studies populations (24). Two studies evaluating hundreds of laboratory-confirmed COVID-19 outpatients have reported the prevalence of symptoms lasting more than 6 months after diagnosis: 33-39% participants with at least one symptom, 14-55% with fatigue, 22% with dyspnea, and 14% with loss of sense of smell or taste (15,16). The differences between studies may be explained by various patients' selection criteria, data collection methods, and definitions of symptoms.

Strikingly, the proportion of COVID-positive patients with long-term symptoms was similar between the three surveyed periods. Our findings are supported by a few longitudinal studies, which analyzed the evolution of residual symptoms and showed a stable proportion after the acute phase and up to 7 months (7,25).

In our study 23% of COVID-positive required at least one additional medical visit for COVID-

19-related symptoms, which is close to the proportion of 36% found in another study (16).

These data show the burden on ambulatory health-care facilities related to post-COVID-19

syndrome. However, we did not find a statistical difference in the proportion of patients

requiring an additional medical consultation between COVID-positive and COVID-negative,

which might be due to a lack of statistical power.

Our results shed more light on the association between SARS-CoV-2 infection and long-term

symptoms. While some symptoms were more frequent in PCR-confirmed COVID-19

outpatients, the prevalence of others was not different to SARS-CoV-2 PCR negative patients.

In particular, the prevalence of headache and sleep disorder, two predominant persisting

symptoms in COVID-negative patients, was similar between COVID-negative and COVID-

positive. Both symptoms may originate from mixed etiologies including psychosocial factors

and/or non-specific post-infectious consequences. The COVID-19 pandemic has greatly

impacted our psychosocial behaviors due to confinement, social distancing, mask wearing and

changing work conditions. Some symptoms may be a consequence of these unprecedented

changes (26). Furthermore, long-term sequelae after an acute respiratory infection may not

be limited to coronaviruses, as shown with severe H7N9 infection leading to lung disability

and psychological impairment at 2 years of follow-up (27).

Another study evaluating 6-month sequelae in outpatients with COVID-19 included a small

control group of healthy volunteers and showed that 33% of COVID-positive outpatients and

5% of volunteers presented symptoms (15). However, the limited sample size (21 healthy

volunteers) and their normal health status prevents comparison with our results. Another

report also showed that 26% of seropositive health care workers present long-term symptoms

8 months after mild COVID, while only 9% of seronegative do (28). Inclusion of patients

irrespective of the presence of symptoms (no or mild prior symptoms) might explain the lower

prevalence compared to our results.

Overweight/obesity was an independent predictor of the presence of any long-term

symptom, fatigue and dyspnea. Overweight and obesity are increasingly associated with poor

outcomes in COVID-19. In a systematic review and meta-analysis of 22 studies and in a large

CDC analysis in the United States population, overweight and/or obesity in COVID-19 were

associated with an increased risk of hospital admission, invasive ventilation, and death,

especially among patients younger than 60 years-old (29,30). Another study reported an

association between body mass index and persisting symptoms after more than 28 days (31).

The mechanisms responsible for post-COVID-19 syndrome are not understood yet and may

be multiple (32,33). Long-term symptoms may be due to higher initial organ damages related

to dysregulated inflammatory response. This may be true in people with overweight and

obesity (34–36), since the adipose tissue has a high expression of angiotensin-converting

enzyme 2 receptors and secretes pro-inflammatory cytokines.

While previous studies showed that male gender is a risk factor for severe outcome in COVID-

19 (37), we identified female gender as a predictor for post-COVID-19 syndrome and

specifically for persisting fatigue and smell or taste disorder. Although not always consistent,

some studies have described an association between female gender and long-COVID (31),

persisting fatigue (12–14), post-exertional polypnea (13), decreased rates of recovery (16),

and anxiety or depression (14,16). Gender differences in immunity, as illustrated by the higher

representation of women in autoimmune diseases (38), may explain divergent findings with

COVID-19.

Our study has some limitations. First, most surveyed symptoms are subjective and prone to

observer bias. Symptoms may also come from an intercurrent condition at the time of COVID-

19 diagnosis and not always represent sequelae of SARS-CoV-2 infection. However, inclusion

of a symptomatic control group supports the association between some symptoms and SARS-

CoV-2 infection. Furthermore, this reflects the clinical reality that physicians face in a post-

COVID consultation. Since the prevalence of most symptoms was lower than 10%, the absence

of difference may be due to a lack of statistical power to detect an association with COVID-19.

Our study suffers from a selection bias due to SARS-CoV-2 test criteria (health care workers or

presence of a risk factor of adverse outcome) at the time of the study, which may prevent

generalization of our findings to the broad population. In addition, we included a SARS-CoV-2

PCR negative control group, who had a slightly different clinical presentation (only patients

with acute respiratory symptoms) compared to COVID-positive (any symptom suggestive of

COVID-19). Furthermore, we cannot formally exclude that some COVID-negative had an

undiagnosed SARS-CoV-2 infection due to a false negative PCR result. However, we used a

validated SARS-CoV-2 RT-PCR test on a nasopharyngeal swab performed by a dedicated

trained medical team to minimize technical and sample collection bias (19,39).

In conclusion, our study shows that more than half of outpatients with mild-to-moderate

COVID-19 report long-term symptoms 3 to 10 months after diagnosis and that 21% seek

medical care for this reason. These data suggest that post-COVID syndrome places a significant

burden on society and especially healthcare systems. There is an urgent need to inform

physicians and political authorities about the natural long-term course of COVID-19 in order

to plan an appropriate and dedicated management of those with disabling persisting

symptoms.

DECLARATIONS

Acknowledgements

We thank all the patients who accepted to participate and make this study possible. We thank all healthcare workers of the triage center and of the emergency department of the University Hospital of Lausanne, who supported the study and managed COVID-19 suspected patients. We thank Nadia Cattaneo and Martin Delaloye who participated to patients' follow-up. We thank Tanguy Espejo and Luca Bosso who included patients in the COVID-negative group.

Members of the RegCOVID group (by alphabetical order): Pierre-Yves Bochud (Committee President), Florian Desgranges, Paraskevas Filippidis, David Haefliger, Eleftheria Evdokia Kampouri, Oriol Manuel (Committee Member), Aline Munting, Jean-Luc Pagani (Committee Member), Matthaios Papadimitriou-Olivgeris (Registry Coordinator and Committee Member), Jean Regina, Laurence Rochat Stettler, Véronique Suttels, Eliana Tadini, Jonathan Tschopp, Mathias Van Singer, Benjamin Viala, Peter Vollenweider (Committee member).

Authors' contributions

FD, MPO, NBB: study conception, study design, study performance, study management, patients' follow-up, data analysis, data interpretation and manuscript writing.

ET, AM: patients follow-up, data interpretation and manuscript writing.

JR, PF, BV, NS, DH, EK, MVS, JT, LRS: patients follow-up, data interpretation and critical review of the manuscript.

BG: study design, data interpretation and critical review of the manuscript.

OH, YMC, AG, PNC, BG: data interpretation and critical review of the manuscript.

EK: data analysis, interpretation, and critical review of the manuscript.

TB, SS: patients' inclusion, and critical review of the manuscript.

OO: microbiological data interpretation and critical review of the manuscript

MPO had full access to all the data in the study and takes responsibility for the integrity

of the data and the accuracy of the data analysis.

Funding

This work was supported by an academic award of the Leenaards Foundation (to NBB),

the Infectious Disease Service and the emergency department of Lausanne University

Hospital. The funding bodies had no role in the design of the study and collection,

analysis, and interpretation of data and in writing the manuscript

BIBLIOGRAPHY

1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020 Feb 20;382(8):727–33.

2. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020 Apr 7;323(13):1239–42.

3. Tenforde MW, Kim SS, Lindsell CJ, Billig Rose E, Shapiro NI, Files DC, et al. Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March–June 2020. MMWR Morb Mortal Wkly Rep. 2020 Jul 31;69(30):993–8.

4. Wang X, Xu H, Jiang H, Wang L, Lu C, Wei X, et al. Clinical features and outcomes of discharged coronavirus disease 2019 patients: a prospective cohort study. QJM: An International Journal of Medicine. 2020 Sep 1;113(9):657–65.

5. Banda JM, Singh GV, Alser OH, Prieto-Alhambra D. Long-term patient-reported symptoms of COVID-19: an analysis of social media data [Internet]. Infectious Diseases (except HIV/AIDS); 2020 Aug [cited 2021 Apr 7]. Available from: http://medrxiv.org/lookup/doi/10.1101/2020.07.29.20164418

6. Goërtz YMJ, Van Herck M, Delbressine JM, Vaes AW, Meys R, Machado FVC, et al. Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? ERJ Open Research. 2020 Oct;6(4):00542–2020.

7. Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re'em Y, et al. Characterizing Long COVID in an International Cohort: 7 Months of Symptoms and Their Impact [Internet]. Infectious Diseases (except HIV/AIDS); 2020 Dec [cited 2021 Jan 19]. Available from: http://medrxiv.org/lookup/doi/10.1101/2020.12.24.20248802

8. Carfì A, Bernabei R, Landi F, Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent Symptoms in Patients After Acute COVID-19. JAMA. 2020 Aug 11;324(6):603–5.

9. Carvalho-Schneider C, Laurent E, Lemaignen A, Beaufils E, Bourbao-Tournois C, Laribi S, et al. Follow-up of adults with noncritical COVID-19 two months after symptom onset. Clinical Microbiology and Infection. 2021 Feb;27(2):258–63.

10. Chopra V, Flanders SA, O'Malley M, Malani AN, Prescott HC. Sixty-Day Outcomes Among Patients Hospitalized With COVID-19. Annals of Internal Medicine [Internet]. 2020 Nov 11 [cited 2021 Feb 12]; Available from: https://www.acpjournals.org/doi/10.7326/M20-5661

11. Garrigues E, Janvier P, Kherabi Y, Le Bot A, Hamon A, Gouze H, et al. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. Journal of Infection. 2020 Dec;81(6):e4–6.

12. Townsend L, Dyer AH, Jones K, Dunne J, Mooney A, Gaffney F, et al. Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. Madeddu G, editor. PLoS ONE. 2020 Nov 9;15(11):e0240784.

13. Xiong Q, Xu M, Li J, Liu Y, Zhang J, Xu Y, et al. Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study. Clinical Microbiology and Infection. 2021 Jan 1;27(1):89–95.

14. Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021 Jan 16;397(10270):220–32.

15. Logue JK, Franko NM, McCulloch DJ, McDonald D, Magedson A, Wolf CR, et al. Sequelae in Adults at 6 Months After COVID-19 Infection. JAMA Netw Open. 2021 Feb 19;4(2):e210830.

16. Menges D, Ballouz T, Anagnostopoulos A, Aschmann HE, Domenghino A, Fehr JS, et al. Estimating the burden of post-COVID-19 syndrome in a population-based cohort study of SARS-CoV-2 infected individuals: Implications for healthcare service planning [Internet]. Epidemiology; 2021 Mar [cited 2021 Mar 7]. Available from: http://medrxiv.org/lookup/doi/10.1101/2021.02.27.21252572

17. National Institute for Health and Care Excellence (NICE), the Scottish Intercollegiate Guidelines Network, (SIGN) and the Royal College of General Practitioners (RCGP). COVID-19 rapid guideline: managing the long-term effects of COVID-19. 2020 Dec 18;35.

18. Office fédéral de la santé publique OFSP. Nouveau Coronavirus (COVID-19) Critères de suspicion, de prélèvement d'échantillons et de déclaration [Internet]. 2020 [cited 2020 Apr 30]. Available from: https://www.bag.admin.ch/bag/fr/home/krankheiten/infektionskrankheiten-bekaempfen/meldesysteme-infektionskrankheiten/meldepflichtige-ik/meldeformulare.html

19. Opota O, Brouillet R, Greub G, Jaton K. Comparison of SARS-CoV-2 RT-PCR on a high-throughput molecular diagnostic platform and the cobas SARS-CoV-2 test for the diagnostic of COVID-19 on various clinical samples. Pathog Dis. 2020 Nov 11;78(8).

20. Brahier T, Meuwly J-Y, Pantet O, Brochu Vez M-J, Gerhard Donnet H, Hartley M-A, et al. Lung ultrasonography for risk stratification in patients with COVID-19: a prospective observational cohort study. Clinical Infectious Diseases. 2020 Sep 17;ciaa1408.

21. Schaad S, Brahier T, Hartley M-A, Cordonnier J-B, Bosso L, Espejo T, et al. Point-of-care lung ultrasonography for early identification of mild COVID-19: a prospective cohort of outpatients in a Swiss screening center. medRxiv. 2021 Mar 26;2021.03.23.21254150.

22. The Criteria Committee of the New York Heart Association . Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. In: 9th ed. Boston, Mass: ed Little, Brown & Co; 1994. p. 253–256.

23. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform. 2019 Jul;95:103208.

24. Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, et al. More than 50 Long-term effects of COVID-19: a systematic review and meta-analysis. medRxiv. 2021 Jan 30;2021.01.27.21250617.

25. Nguyen NN, Hoang VT, Lagier J-C, Raoult D, Gautret P. Long-term persistence of olfactory and gustatory disorders in COVID-19 patients. Clinical Microbiology and Infection. 2021 Jan;S1198743X20307813.

26. Alzueta E, Perrin P, Baker FC, Caffarra S, Ramos-Usuga D, Yuksel D, et al. How the COVID-19 pandemic has changed our lives: A study of psychological correlates across 59 countries. Journal of Clinical Psychology. 2021;77(3):556–70.

27. Chen J, Wu J, Hao S, Yang M, Lu X, Chen X, et al. Long term outcomes in survivors of epidemic Influenza A (H7N9) virus infection. Scientific Reports. 2017 Dec 8;7(1):17275.

28. Havervall S, Rosell A, Phillipson M, Mangsbo SM, Nilsson P, Hober S, et al. Symptoms and Functional Impairment Assessed 8 Months After Mild COVID-19 Among Health Care Workers. JAMA [Internet]. 2021 Apr 7 [cited 2021 Apr 18]; Available from: https://jamanetwork.com/journals/jama/fullarticle/2778528

29. Chu Y, Yang J, Shi J, Zhang P, Wang X. Obesity is associated with increased severity of disease in COVID-19 pneumonia: a systematic review and meta-analysis. European Journal of Medical Research. 2020 Dec 2;25(1):64.

30. Kompaniyets L, Goodman AB, Belay B, Freedman DS, Sucosky MS, Lange SJ, et al. Body Mass Index and Risk for COVID-19–Related Hospitalization, Intensive Care Unit Admission, Invasive Mechanical Ventilation, and Death — United States, March–December 2020. MMWR Morb Mortal Wkly Rep. 2021 Mar 12;70(10):355–61.

31. Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. Attributes and predictors of long COVID. Nature Medicine. 2021 Mar 10;1–6.

32. Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, et al. Extrapulmonary manifestations of COVID-19. Nat Med. 2020/07/12. 2020 Jul;26(7):1017–32.

33. Wang F, Kream RM, Stefano GB. Long-Term Respiratory and Neurological Sequelae of COVID-19. Med Sci Monit. 2020 Nov 1;26:e928996-1-e928996-10.

34. Albashir AAD. The potential impacts of obesity on COVID-19. Clin Med (Lond). 2020 Jul;20(4):e109–13.

35. Dicker D, Bettini S, Farpour-Lambert N, Frühbeck G, Golan R, Goossens G, et al. Obesity and COVID-19: The Two Sides of the Coin. OFA. 2020;13(4):430–8.

36. Stefan N, Birkenfeld AL, Schulze MB. Global pandemics interconnected — obesity, impaired metabolic health and COVID-19. Nature Reviews Endocrinology. 2021 Jan 21;1–15.

37. Peckham H, de Gruijter NM, Raine C, Radziszewska A, Ciurtin C, Wedderburn LR, et al. Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. Nat Commun. 2020 Dec;11(1):6317.

38. Ngo ST, Steyn FJ, McCombe PA. Gender differences in autoimmune disease. Front Neuroendocrinol. 2014 Aug;35(3):347–69.

39. Mueller L, Scherz V, Greub G, Jaton K, Opota O. Computer-aided medical microbiology monitoring tool: a strategy to adapt to the SARS-CoV-2 epidemic and that highlights RT-PCR consistency [Internet]. Infectious Diseases (except HIV/AIDS); 2020 Jul [cited 2021 Apr 5]. Available from: http://medrxiv.org/lookup/doi/10.1101/2020.07.27.20162123

TABLES

Table 1: Characteristics of patients according to SARS-CoV-2 RT-PCR result (COVID-negative and COVID-positive).

Characteristics	COVID-negative (N=89)	COVID-positive (N=418)	P value
Demographics			
Age in years	36 (29-47)	41 (31-54)	0.020
Female gender	57 (64%)	261 (62%)	0.776
Active smoking	27 (30%)	46 (11%)	<0.001
Health care worker	73 (82%)	281 (67%)	0.006
BMI (kg/m^2)	24 (22-27)	24 (22-28)	0.412
Comorbidities			
Any comorbidity	32 (36%)	130 (31%)	0.372
Arterial Hypertension	8 (9.0%)	65 (16%)	0.109
Diabetes Mellitus	1 (1.1%)	22 (5.3%)	0.098
Cardiovascular Disease	5 (5.6%)	10 (2.4%)	0.157
Asthma	16 (18%)	43 (10%)	0.040
Malignancy (hematological/solid organ)	0 (0.0%)	15 (3.6%)	0.085
Chronic inflammatory disease	1 (1.1%)	13 (3.1%)	0.482
Overweight [a] or obesity	36 (40%)	189 (45%)	0.411
Obesity	11 (12%)	72 (17%)	0.260
Other comorbidities[b]	4 (4.5%)	12 (2.9%)	0.500
Symptoms at initial consultation			
Days from symptoms onset	2.0 (2.0-4.0)	3.0 (2.0-7.0)	0.088
Fever	52 (58%)	172 (41%)	0.003
Sore throat	35 (39%)	79 (19%)	<0.001
Rhinorrhoea	43 (48%)	205 (49%)	0.901
Smell or taste disorder	9 (10%)	73 (17%)	0.087
Cough	68 (76%)	305 (73%)	0.504
Dyspnea	49 (55%)	67 (16%)	<0.001
Myalgia/arthralgia	53 (60%)	249 (60%)	0.997
Diarrhea	19 (21%)	60 (14%)	0.099
Signs at initial consultation			
Temperature (°C)	36.9 (36.6-37.3)	37.2 (36.7-37.9)	<0.001
Heart rate (beats/min)	90 (78-98)	86 (75-98)	0.168
Respiratory rate (breath/min)	18 (16-20)	17 (15-20)	0.419
SpO$_2$ on ambient air (%)	97 (97-98)	97 (96-98)	0.405
Microbiological information			
SARS-CoV-2 cycle threshold value	-	22 (18-27)	-
Outcome			
Consultation for persisting symptoms	13 (15%)	87 (21%)	0.182

Data are number (%) of patients or median (interquartile range).
[a]"Any comorbidity" does not included overweight; [b]Other comorbidities: 7 Neurological Disease, 5 Chronic Kidney Disease, 4 Chronic Obstructive Pulmonary Disease, 4 Cirrhosis.

Missing data: 1 BMI, 98 days from symptoms onset, 39 temperature, 84 heart rate, 310 respiratory rate, 41 SpO2 on ambient air, 7 SARS-CoV-2 cycle threshold value.

Two-sided chi-squared or Fisher tests were performed when comparing proportions, and Mann–Whitney U tests were performed for continuous variables.

BMI: body mass index; SpO2: oxygen saturation; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; RT-PCR: real time reverse transcriptase polymerase chain reaction.

Table 2. Association between long-term symptoms (any and individualized symptoms) assessed at the time of phone survey and COVID positive status.

Long-term symptoms	COVID-negative (n=89)	COVID-positive (n=418)	Bivariate analysis * OR (95% CI)	P value	Multivariable analysis * ° aOR (95% CI)	P value
Any symptoms	33 (37%)	223 (53%)	1.94 (1.21-3.11)	0.006	2.04 (1.14-3.67)	0.017
Fatigue	15 (17%)	132 (32%)	2.28 (1.26-4.12)	0.006	2.14 (1.04-4.41)	0.039
Muscle weakness	2 (2.2%)	8 (1.9%)	0.85 (0.18-4.07)	0.837	0.65 (0.08-5.21)	0.688
Dyspnea	7 (7.9%)	66 (16%)	2.20 (0.97-4.96)	0.059	2.81 (1.10-7.16)	0.030
Dyspnea NYHA≥2	4 (4.5%)	30 (7.2%)	1.64 (0.56-4.79)	0.363	1.11 (0.29-4.32)	0.881
Cough	3 (3.4%)	25 (6.0%)	1.82 (0.54-6.2)	0.334	1.16 (0.24-5.56)	0.849
Thoracic pain	4 (4.5%)	21 (5.0%)	1.12 (0.38-3.36)	0.834	1.11 (0.27-4.54)	0.886
Smell or taste disorder	1 (1.1%)	93 (22%)	25.2 (3.46-183)	0.001	26.5 (3.46-202)	0.002
Blurred vision	2 (2.2%)	20 (4.8%)	2.19 (0.50-9.53)	0.298	3.17 (0.63-16.0)	0.163
Headache	10 (11%)	50 (12%)	1.07 (0.52 -2.21)	0.847	1.27 (0.52-3.09)	0.601
Loss of balance	3 (3.4%)	12 (2.9%)	0.85 (0.23-3.07)	0.801	0.37 (0.05-2.62)	0.322
Memory impairment	3 (3.4%)	48 (11%)	3.72 (1.13-12.2)	0.003	5.71 (1.53-21.3)	0.010
Numbness	1 (1.1%)	14 (3.4%)	3.05 (0.40-23.5)	0.284	1.71 (0.14-20.3)	0.670
Nausea	3 (3.4%)	11 (2.6%)	0.77 (0.21-2.84)	0.700	1.30 (0.24-7.08)	0.760
Sleep disorder	10 (11%)	41 (9.8%)	0.86 (0.41-1.79)	0.685	1.03 (0.42-2.52)	0.950
Hair loss	5 (5.6%)	43 (10%)	1.92 (0.74-5.01)	0.179	1.18 (0.36-3.93)	0.783

Data are number (%) of patients. *symptoms associated with COVID-positive status. ° analysis adjusted for age, sex, smoking, overweight/obesity, diabetes, asthma, hypertension, cancer, cardiovascular disease, chronic inflammatory disease, period of the phone survey.
OR: odds ratio; aOR: adjusted odds ratio; CI: confidence interval; NYHA: New York Heart Association.

Table 3. Factors associated with the presence of any long-term symptom during the phone survey in COVID-positive patients.

Characteristics	No symptom (n=195)	Any symptom (n=223)	Bivariate analysis *		Multivariable analysis * °	
			OR (95% CI)	P value	aOR (95% CI)	P value
Demographics						
Age in years	41 (30-54)	42 (33-54)	1.01 (0.95-1.08)	0.702	1.02 (0.94 to 1.10)	0.682
Female gender	112 (57%)	149 (67%)	1.49 (1.00-2.22)	0.049	1.67 (1.09 to 2.56)	0.019
Active smoking	16 (8.2%)	30 (13%)	1.74 (0.92-3.30)	0.090	1.72 (0.89 to 3.34)	0.107
Comorbidities						
Overweight or obesity	78 (40%)	112 (50%)	1.50 (1.02-2.21)	0.041	1.67 (1.10 to 2.56)	0.017
Diabetes Mellitus	12 (6.2%)	10 (4.5%)	0.72 (0.30-1.70)	0.447	0.69 (0.28 to 1.72)	0.426
Asthma	19 (9.7%)	24 (11%)	1.12 (0.59-2.11)	0.732	1.11 (0.58 to 2.14)	0.749
Hypertension	30 (15%)	35 (16%)	1.02 (0.60-1.74)	0.930	0.96 (0.51 to 1.81)	0.912
Malignancy	5 (2.6%)	10 (4.5%)	1.78 (0.60-5.31)	0.298	1.63 (0.50 to 5.30)	0.414
Cardiovascular Disease	5 (2.6%)	5 (2.2%)	0.87 (0.25-3.06)	0.830	1.05 (0.27 to 4.09)	0.948
Chronic inflammatory Disease	5 (2.6%)	8 (3.6%)	1.41 (0.45-4.40)	0.549	1.18 (0.35 to 3.94)	0.790
Timing of phone survey						
>3 to 5 months	87 (45%)	103 (46%)	1.07 (0.72-1.57)	0.747	1.06 (0.65 to 1.73)	0.808
>5 to 7 months	47 (24%)	55 (25%)	1.03 (0.66-1.61)	0.894	1.05 (0.61 to 1.80)	0.856
>7 to 10 months	61 (31%)	65 (29%)	0.90 (0.59-1.37)	0.635	1.00 (reference)	

Data are number (%) of patients or median (interquartile range). *symptoms associated with the presence of any long-term symptom. ° analysis adjusted for age, sex, smoking, overweight/obesity, diabetes, asthma, hypertension, cancer, cardiovascular disease, chronic inflammatory disease, period of the phone survey.
Missing data: 1 BMI
Odds ratio for age indicates the risk of the presence of any symptom per 5-year age increase.
OR: odds ratio; aOR: adjusted odds ratio; CI: confidence interval.

FIGURE LEGENDS

Figure 1: Study flow-chart

Figure 2: Proportions of patients with long-term symptoms at the time of the phone survey.

A) Comparison between COVID-positive (positive SARS-CoV-2 RT-PCR) and COVID-negative (negative SARS-CoV-2 RT-PCR); **B)** Comparison between COVID-positive surveyed during three different period: Period 1: >3 to 5 months after SARS-CoV-2 diagnosis; Period 2: >5 to 7 months after SARS-CoV-2 diagnosis; Period 3: >7 to 10 months after SARS-CoV-2 diagnosis. Data are shown as proportions (%) with 95% confidence intervals.

Figure 3: Factors associated with the presence of selected long-term symptoms (fatigue, smell or taste disorder, dyspnea and memory impairment) during the phone survey in COVID-positive patients.

Selected symptoms are those associated with COVID status.

Multivariable analysis adjusted for age, sex, smoking, overweight/obesity, diabetes, asthma, hypertension, cancer, cardiovascular disease, chronic inflammatory disease, period of the phone survey. Adjusted odds ratio for age indicates the risk of fatigue, smell/taste disorder, dyspnea or memory impairment per 5-year age increase.

aOR: adjusted odds ratio; CI: confidence interval.

*$p<0.05$

A

B

Fatigue

	aOR (95% CI)
Age	1.08 (0.99 to 1.17)
Women	1.61 (1.00 to 2.59) *
Current smoker	1.79 (0.92 to 3.46)
Overweigth/Obesity	1.70 (1.08 to 2.67) *
Diabetes	0.76 (0.27 to 2.13)
Asthma	0.95 (0.46 to 1.95)
Hypertension	1.00 (0.51 to 1.93)
Malignancy	0.80 (0.25 to 2.57)
Cardiovascular Disease	0.21 (0.03 to 1.81)
Chronic Inflammatory Disease	3.40 (1.00 to 11.6)
Timing of phone survey	
>3 to 5 months	1.23 (0.73 to 2.10)
>5 to 7 months	1.27 (0.71 to 2.29)
>7 to 10 months	1.00 (ref)

Smell/Taste disorder

	aOR (95% CI)
Age	0.98 (0.88 to 1.07)
Women	1.88 (1.09 to 3.22) *
Current smoker	1.82 (0.92 to 3.62)
Overweigth/Obesity	1.01 (0.61 to 1.67)
Diabetes	1.14 (0.39 to 3.38)
Asthma	1.17 (0.55 to 2.46)
Hypertension	1.31 (0.61 to 2.78)
Malignancy	0.92 (0.23 to 3.66)
Cardiovascular Disease	1.13 (0.21 to 6.11)
Chronic Inflammatory Disease	0.74 (0.15 to 3.65)
Timing of phone survey	
>3 to 5 months	1.05 (0.58 to 1.90)
>5 to 7 months	1.44 (0.77 to 2.69)
>7 to 10 months	1.00 (ref)

Dyspnea

	aOR (95%)
Age	0.93 (0.83 to 1.05)
Women	1.71 (0.93 to 3.16)
Current smoker	1.15 (0.51 to 2.61)
Overweigth/Obesity	2.02 (1.14 to 3.59) *
Diabetes	0.23 (0.03 to 1.84)
Asthma	1.05 (0.43 to 2.53)
Hypertension	1.19 (0.51 to 2.82)
Malignancy	0.33 (0.04 to 2.88)
Cardiovascular Disease	2.57 (0.45 to 14.6)
Chronic Inflammatory Disease	2.07 (0.50 to 8.63)
Timing of phone survey	
>3 to 5 months	0.83 (0.43 to 1.60)
>5 to 7 months	0.90 (0.44 to 1.85)
>7 to 10 months	1.00 (ref)

Memory impairment

	aOR (95%)
Age	0.98 (0.85 to 1.12)
Women	1.10 (0.56 to 2.17)
Current smoker	3.51 (1.63 to 7.58) *
Overweigth/Obesity	1.79 (0.93 to 3.44)
Diabetes	0.76 (0.16 to 3.67)
Asthma	1.24 (0.47 to 3.29)
Hypertension	0.93 (0.33 to 2.64)
Malignancy	2.96 (0.64 to 13.6)
Cardiovascular Disease	1.02 (0.11 to 9.83)
Chronic Inflammatory Disease	1.00 (1.00 to 1.00)
Timing of phone survey	
>3 to 5 months	0.73 (0.33 to 1.62)
>5 to 7 months	1.27 (0.57 to 2.80)
>7 to 10 months	1.00 (ref)